Efficacy and safety of PD-1 immune checkpoint inhibitors in locally advanced and advanced non-small cell lung cancer patients with chronic viral infection

Zhiting Zhao[1], Ran Hu[1], Yan Chen[2], Guoren Zhou[2], Shaorong Yu[2], and Jifeng Feng[2]

[1]Jiangsu Cancer Hospital
[2]Affiliation not available

July 19, 2021

Abstract

Abstract Immune checkpoint inhibitors (ICIs) have become new research hotspots in the treatment of non-small cell lung cancer, but the efficacy and safety of immunotherapy for patients with chronic viral infection are still unclear, because existing clinical trials often exclude those patients. Materials and Methods We identified 78 locally advanced or advanced NSCLC patients with chronic viral infection treated with PD-1/PD-L1 inhibitors alone or combined with the chemotherapy/bevacizumab therapy, of whom 60 with hepatitis B, 2 with hepatitis C, and 16 with syphilis. Objective response rates were assessed using the RECIST v1.1. Adverse events were graded following the National Cancer Institute Common Terminology Criteria for Adverse Events v5.0. Results Objective responses were observed in 19 out of 78(24.36%) patients, and the disease control rate (DCR) was 69.23% (54/78). No patient achieved a complete response. The median progression-free survival (PFS) was 6.49 months (95% CI:3.71-9.27). PFS was 1.44 months (95%CI:0.00-4.34) for monotherapy versus 7.34 months (95%CI:4.50-10.18) for combination therapy (P=0.053). Patients in the first-line treatment group revealed relatively higher ORR and longer PFS (ORR: 48.00% vs. 13.20%, P = 0.001; PFS: 7.67 months vs. 5.57 months, P = 0.129). Patients with combined radiotherapy showed longer PFS than those without combined radiotherapy (14.07 vs.4.62, P=0.027). The incidence of adverse events of any grade was 73.07% (57/78), among which there were 7 cases of grade 4 adverse events. The incidence of leukopenia in any grade of adverse reactions was the highest (57.69%), followed by anemia (25.64%), elevated alanine aminotransferase or aspartate aminotransferase (24.36%) and fatigue (21.79%). Hepatic transaminase increased in 26.7% (16/60) of HBV-infected patients, and remained unchanged in 63.3% (38/60) patients. Conclusions The PD-1 inhibitor showed an acceptable toxicity profile and moderate efficacy on NSCLC patients with chronic viral infection, but still has the potential to increase the incidence of hepatitis.

Efficacy and safety of PD-1 immune checkpoint inhibitors in locally advanced and advancednon-small cell lung cancer patients with chronic viral infection

Abstract

Immune checkpoint inhibitors (ICIs) have become new research hotspots in the treatment of non-small cell lung cancer, but the efficacy and safety of immunotherapy for patients with chronic viral infection are still unclear, because existing clinical trials often exclude those patients.

Materials and Methods

We identified 78 locally advanced or advanced NSCLC patients with chronic viral infection treated with PD-1/PD-L1 inhibitors alone or combined with the chemotherapy/bevacizumab therapy, of whom 60 with hepatitis B, 2 with hepatitis C, and 16 with syphilis. Objective response rates were assessed using the RECIST v1.1. Adverse events were graded following the National Cancer Institute Common Terminology Criteria for Adverse Events v5.0.

Results

Objective responses were observed in 19 out of 78(24.36%) patients, and the disease control rate (DCR) was 69.23% (54/78). No patient achieved a complete response. The median progression-free survival (PFS) was 6.49 months (95% CI:3.71-9.27). PFS was 1.44 months (95%CI:0.00-4.34) for monotherapy versus 7.34 months (95%CI:4.50-10.18) for combination therapy (P=0.053). Patients in the first-line treatment group revealed relatively higher ORR and longer PFS (ORR: 48.00% vs. 13.20%, P = 0.001; PFS: 7.67 months vs. 5.57 months, P = 0.129). Patients with combined radiotherapy showed longer PFS than those without combined radiotherapy (14.07 vs.4.62, P=0.027). The incidence of adverse events of any grade was 73.07% (57/78), among which there were 7 cases of grade 4 adverse events. The incidence of leukopenia in any grade of adverse reactions was the highest (57.69%), followed by anemia (25.64%), elevated alanine aminotransferase or aspartate aminotransferase (24.36%) and fatigue (21.79%). Hepatic transaminase increased in 26.7% (16/60) of HBV-infected patients, and remained unchanged in 63.3% (38/60) patients.

Conclusions

The PD-1 inhibitor showed an acceptable toxicity profile and moderate efficacy on NSCLC patients with chronic viral infection, but still has the potential to increase the incidence of hepatitis.

Keywords : immune checkpoint inhibitors; A history of infection; Non-small cell lung cancer; Programmed cell death-1

WHAT'S KNOWN?

Successful anti-PD-1 / PD-L1 immunotherapy requires an adequate number of specific T cells in the tumor microenvironment. Similar to the tumor microenvironment, the chronic viral infection is a strong immunosuppression environment, leading to specific T cells exhausting, in theory, it may influence the effect of ICI which has reversed the role of T cell failure at the same time and undermine the balance between the host immune system and virus control that has caused the risk of liver damage. But there is not any consensus yet and appropriate strategy of ICIs in this population needs in depth assessment. In the existing published articles about safety and efficacy of ICIs in patients with chronic viral infection and advanced-stage cancer, the types of cancer involved are not comprehensive, with liver cancer and melanoma accounting for the majority and NSCLC accounting for less than five percent. In one retrospective study of PD-1 inhibitors for NSCLC with special issues involving 32 HBV-infected patients, four of nine patients experienced severe AST/ALT elevation (grade 3 or higher) were HBV patients. And three patients developed viral reactivations or flares, despite receiving anti-HBV therapy prior to the immunotherapy.

WHAT'S NEW?

By expanding the sample size, we found that the PD-1 inhibitor showed an acceptable toxicity profile on NSCLC patients with chronic viral infection. There is no big difference between the adverse reaction spectrum and the incidence of adverse reactions in such patients and those of patients without infectious diseases, but it is worth observing that the proportion of hepatic transaminase elevating was increased. Hepatic transaminase increased in 26.7% (16/60) of hepatitis B patients. All five patients with reduced viral load received antiviral therapy. Of the 14 patients who did not receive antiviral therapy, 3 patients had grade 3 or 4 adverse events, but in all three patients, the adverse events were reversed with steroids and ICIs were not discontinued, so the side effects were considered acceptable. And immunotherapy combined with antiviral therapy can effectively improve safety. Therefore, we recommend close monitoring for such patients in consultation with a hepatologist and to treat those with active viral hepatitis with antiviral therapy prior to the immunotherapy. The efficacy of PD-1/PD-L1 immune checkpoint inhibitors on locally advanced and advanced NSCLC patients with a history of infectious diseases was acceptable and such patients can benefit from immunotherapy. In subgroup analysis, first-line treatment group, immunotherapy combined with radiotherapy group, immunotherapy combined with chemotherapy and antiangiogenic agents group showed better efficacy.

Introduction

Lung cancer is one of the leading causes of cancer-related deaths worldwide [1], and non-small cell lung cancer (NSCLC) accounts for more than 80% of all lung cancers. Despite the existence of various treatment methods such as new chemotherapeutics and gene-targeted drugs, still patients with lung cancer have below 5-year survival rate and high mortality rate. In recent years, immunotherapy, especially PD-1/PD-L1 immune checkpoint inhibitors, has achieved a great success in the clinical application of various tumors by inhibiting the PD-1/PD-L1 signaling pathway and activating the immune system. Therefore, it has fetched much attentions of the researchers recently.

However, existing clinical trials often exclude patients with viral infections (patients with hepatitis B, hepatitis C, syphilis, etc.), and the efficacy and safety of immunotherapy for such patients are still unclear. There is a high occurrence of hepatitis B in China and the current hepatitis B surface antigen carrying rate of people under 60 is 7.2% [2]. There are about 93 million chronic HBV infections, of which more than 20 million are patients with active hepatitis B [3]. The purpose of current investigation is to retrospectively analyze the efficacy and safety of PD-1 immune checkpoint inhibitors for locally advanced and advanced NSCLC patients with chronic viral infection, to provide a reference for clinical decision-making.

Patients and Methods

Patients

We studied the medical records of all locally advanced and advanced NSCLC patients treated at the Jiangsu Cancer Hospital between May 2018 and March 2021 and identified patients who received the PD-1 inhibitor alone or in combination with the chemotherapy and/or the bevacizumab therapy and screened patients who met one or more of the following criteria: positive for hepatitis B surface antigen; HCV - RNA positive; Syphilis antibody positive. All patients included in this study had at least one measurable disease. This study was approved by the Academic Ethics Committee of Jiangsu Cancer Hospital.

Data collection and response assessment

Medical records were examined and separated on clinical pathologic features and treatment histories. Data and follow-up records were updated as of March 1, 2021. The best response to PD-1 inhibitor-based therapy, defined as a complete or partial response and stable disease achieved at least once during therapy, was assessed using the RECIST v 1.1 criteria. The PFS was defined from the time of treatment initiation to clinical or radiographic progression or death. Adverse events (AEs) were graded by the National Cancer Institute Common Terminology Criteria for Adverse Events v5.0.

Statistical analysis

Survival data were estimated using the Kaplan–Meier method and compared using the log-rank test in the overall cohort and other subgroups. Statistical analyses were performed using the SPSS version 25.0 (SPSS, Inc). P [?] 0.05 was considered to indicate statistical significance.

Results

Patients' characteristics

In this study, we considered 78 patients with chronic viral infection who were treated at Jiangsu Cancer Hospital with the PD-1 inhibitor alone or in combination with the chemotherapy and/or the bevacizumab therapy, and their clinical and pathological baseline characteristics are shown in Table 1. The median age of the 78 patients was 65 years, including 62 males and 16 females. Adenocarcinoma was the most common pathological type (56.4%), followed by squamous cell carcinoma (35.9%). Most of the patients (88.5%) were clinically diagnosed with stage IV lung cancer. Out of 78 patients, 60 were suffering from NSCLC with a history of hepatitis B (including 57 patients with past hepatitis B and 3 patients with chronic hepatitis B), 2 NSCLC patients had the record of hepatitis C, and 16 with syphilis. All patients received PD-1/PD-L1 immune checkpoint inhibitors, including 10 patients were treated with monotherapy and 68 patients were prescribed with the combination chemotherapy/bevacizumab. Most of the patients (67.9%) received the PD-

1 inhibitor-based therapy as second- or late-line therapy and most of the patients (87.2%) did not received combined radiotherapy. Most patients (85.9%) had an ECOG performance status of 0 or 1.

Overall clinical outcomes

As shown in Figure 1A, Objective Radiographic Responses (ORR) was observed in 19 of 78(24.36%) patients, and the disease control rate (DCR) was 69.23% (54/78). No patient achieved a complete response. The median PFS was 6.49 months with a 95% CI of 3.71-9.27 months (Figure 1B). Among those 19 patients who achieved a partial response, 17 were treated with the combination chemotherapy/bevacizumab and only 2 had the PD-1 inhibitor monotherapy, but the results showed no statistically significant difference.

Subgroup analyses

As displayed in Figure 1C , all 10 patients in the combined radiotherapy group were in a more stable condition than that in the non-combined radiotherapy group (DCR=100.00%) ($P < 0.05$) ,and patients with better performance status exhibited a trend of higher DCR than those with poorer performance status (88.23% vs.74.00% vs.18.18%) ($P < 0.05$). Patients in the first-line treatment group (ORR=48.0%) revealed relatively higher ORR and longer PFS than those treated with the PD-1 inhibitor-based therapy as second- or late-line therapy (ORR: 48.00% vs. 13.20%, $P = 0.001$, Figure 1D ; PFS: 7.67 months vs. 5.57 months, $P = 0.129$, Figure 2A). As shown in Figure 2B, PFS was 1.44 months (95%CI:0.00-4.34) for monotherapy versus 7.34 months (95%CI:4.50-10.18) for combination therapy (P=0.053), which was not statistically significant, but it was worth observing that 17 out of the 19 (89.47%) patients who achieved a partial response were on combination therapy. Significant difference was observed in the PFS of different combination groups (PD-1 antibody alone vs. PD-1 antibody combined with the chemotherapy vs. PD-1 antibody combined with the bevacizumab vs. PD-1 antibody combined with the chemotherapy and the bevacizumab groups: 1.44 vs.5.67 vs.1.67 vs.14.13, Figure 2C). Patients with combined radiotherapy showed longer PFS than those without combined radiotherapy (14.07 vs.4.62, P=0.027) (Figure 2D). The evaluation of lesion for the efficacy of ICI therapy and irradiation site were the same sites in all the patients treated with radiotherapy, and the treatment processes are presented in Table 2.

Safety

As shown in the Table 3, the incidence of any grade treatment-related AEs was 73.07% (57/78), including 7 cases of grade 4 adverse reactions, 3 cases of myelosuppression, 2 cases of pneumonia, 1 case of superior vena cava occlusion, and 1 case of ketoacidosis. No fatal effects happened. Among the treatment-related AEs, the incidence of leukopenia was the highest (57.69%), followed by anemia (25.64%), elevated alanine aminotransferase or aspartate aminotransferase (24.36%) and fatigue (24.59%).

Discussion

In this retrospective study, we have evaluated the efficacy and the safety of the PD-1 inhibitor on locally advanced and advanced NSCLC patients with chronic viral infection. Results show that the PD-1 inhibitor-based therapy, especially combined with chemotherapy and bevacizumab, had moderate efficacy on this population. Notably, the incidence of elevated hepatic transaminase was higher in them than those without chronic viral infection and other toxicity profile was acceptable.

In recent past, immunotherapy, especially PD-1/PD-L1 immune checkpoint inhibitors, has brought new hope for lung cancer patients by activating the autoimmune system to achieve the effect of killing tumors. Successful anti-PD-1 / PD-L1 immunotherapy requires an adequate number of specific T cells in the tumor microenvironment. Similar to the tumor microenvironment, the chronic viral infection is a strong immunosuppression environment, leading to specific T cells exhausting[4], in theory, it may influence the effect of ICI which has reversed the role of T cell failure at the same time and undermine the balance between the host immune system and virus control that has caused the risk of liver damage. In China the incidence of hepatitis B is higher. At present, the hepatitis B surface antigen carrying rate among people aged 1-59 is 7.2%. There are about 93 million chronic HBV infected people in China, among which more than 20 million active hepatitis B patients require proper treatment. The efficacy and safety of immunotherapy for these

patients need to be clarified, but existing clinical trials tend to exclude patients with co-viral infection[5].Thus there is not any consensus yet and appropriate strategy of ICIs in this population needs in depth assessment.

In the existing published articles about safety and efficacy of ICIs in patients with chronic viral infection and advanced-stage cancer, the types of cancer involved are not comprehensive, with liver cancer and melanoma accounting for the majority and NSCLC accounting for less than five percent [6]. In one retrospective study of PD-1 inhibitors for NSCLC with special issues involving 32 HBV-infected patients, four of nine patients experienced severe AST/ALT elevation (grade 3 or higher) were HBV patients. And three patients developed viral reactivations or flares, despite receiving anti-HBV therapy prior to the immunotherapy. In our study, the incidence of elevated ALT/AST and increased virus-load was lower than in that study. Differences in ECOG performance status, prior lines of therapy, and agents combined with PD-1 antibody of the patients may contribute to the differences between the two studies[7]. Given the unavailability of such information and the limited number of patients in that study, the results of the two studies were not comparable.

Among 78 patients included in the study, the objective response rate (ORR) was 24.36% (19/78), and the disease control rate (DCR) was 69.23% (54/78). Comparing the phase III clinical trial Keynote-042 in the Chinese subgroup study[8], the exclusion criteria of which included patients with a history of infectious diseases, the overall objective response rate of the immunotherapy group was similar to the results of this study (24.36% vs. 32.80%) (P=0.250), indicating that the history of infectious diseases does not affect the short-term efficacy. In terms of long-term efficacy, the median progression-free survival (PFS) reached 6.49 months (95% CI :3.71-9.27). Among them, the first-line treatment shows better efficacy than the second-line and later treatment (7.67 months vs. 5.57 months, P = 0.129). Previous studies have proved that the median progression-free survival of advanced NSCLC who received pembrolizumab as the first-line immunotherapy was about 8 months[9,10], which is similar to our study, and that of advanced NSCLC who received nivolumab as the second-line immunotherapy was about 3 months[11,12]. In our study, the median PFS of second- and later-line treatment group seems improved than the previous studies. This phenomenon may be because the patients' constitutions are different. In our study, 11.5% of patients were clinically diagnosed with stage IIIB lung cancer, which may have improved the results.

In our group analysis, the short-term efficacy of patients in the first-line treatment group was significantly better than that in the second-and multi-line treatment groups (48.00% vs. 13.20%) (P<0.05). The reason may be that patients in the first-line treatment group have not received other treatments, and there are more specific T cells in the tumor microenvironment than in second-line and multi-line patients, which promote the immune system to recover to a greater extent. The ECOG score of group 0 and group 1 was significantly higher than that of group 2 (88.23% vs.74.00% vs.18.18%) (P<0.05), indicating that patients with better physical conditions are more likely to benefit. The ECOG score of group 2 has poor efficacy, but no deaths related to adverse reactions of immunotherapy occurred, and the safety was fair. The 10 patients in the combined radiotherapy group were all in stable condition, which was better than the non-radiotherapy group, and the PFS was also significantly longer than the patients without combined radiotherapy (14.07 vs.4.62, P=0.027). Because local radiotherapy has a synergistic effect with immunotherapy by enhancing the uptake of antigen by APC, promoting DC activation and migration, and tumor-associated antigen cross-presentation[13]. We divided patients into four groups in accordance with the different agents that were used to combine with the PD-1 inhibitor, drawing the conclusion that patients who received the PD-1 inhibitor in combination with the chemotherapy and the bevacizumab therapy obtained the longest PFS (PD-1 antibody alone vs. PD-1 antibody combined with the chemotherapy vs. PD-1 antibody combined with the bevacizumab vs. PD-1 antibody combined with the chemotherapy and the bevacizumab groups: 1.44 vs.5.67 vs.1.67 vs.14.13, P=0.002), which is consistent with previous research.

The incidence of adverse events of any group among 78 patients was 73.07% (57/78), including 7 cases of grade 4 adverse reactions, 3 cases of bone marrow suppression, 2 cases of pneumonia, 1 case of superior vena cava obstruction, and 1 case of ketoacidosis. 3 patients who died due to respiratory failure after receiving immunotherapy for 2 months were considered to be affected by rapid tumor progression. The incidence of leukopenia in any grade of adverse reactions was the highest (57.69%), followed by anemia (25.64%), hepatic

transaminase elevating (24.36%) and fatigue (21.79%). There is no big difference between the adverse reaction spectrum and the incidence of adverse reactions in patients with infectious diseases and those of patients without infectious diseases, but it is worth observing that the proportion of hepatic transaminase elevating was increased. In the clinical phase III trials of Keynote001, the proportion of alanine aminotransferase (ALT) elevating and aspartate aminotransferase (AST) elevating were respectively 2.2% and 3.0% in the treatment of pembrolizumab.[14] Compared with patients without a history of infectious diseases, the patients in this study displayed a higher incidence of hepatotoxicity. Hepatic transaminase increased in 26.7% (16/60) of hepatitis B patients, and remained unchanged in 63.3% (38/60) patients, as is shown in Table 4. Notably, 5% of hepatitis B patients showed a decrease in hepatic transaminase. Of the 60 patients with hepatitis B, viral load remained unchanged in 53, viral load increased in 2, and viral load decreased in 5. All five patients with reduced viral load received antiviral therapy. Of the 14 patients who did not receive antiviral therapy, 3 patients had grade 3 or 4 adverse events, but in all three patients, the adverse events were reversed with steroids and ICIs were not discontinued, so the side effects were considered acceptable. In summary, there was no significant increase in the incidence of these adverse events in patients with a history of infectious diseases. Considering the retrospective nature of our study and small sample size, data from phase IV studies with relaxed inclusion criteria or from further prospective series are needed to shed more light on the safety and efficacy of ICIs in this challenging population.

In this retrospective analysis, the efficacy of PD-1/PD-L1 immune checkpoint inhibitors on locally advanced and advanced NSCLC patients with a history of infectious diseases was acceptable, safe, and the clinical outcome was not affected by the history of infectious diseases. Such patients can benefit from immunotherapy. However, considering that the incidence of hepatic transaminase elevating has increased, we recommend close monitoring for such patients in consultation with a hepatologist and to treat those with active viral hepatitis with antiviral therapy prior to the immunotherapy.

Acknowledgments

This work was supported by the National Natural Science Foundation of China [81871873]; the Project of Invigorating Health Care through Science, Technology, and Education, Jiangsu Provincial Medical Youth Talent [QNRC2016646]; China Postdoctoral Science Foundation [2017M621680]; Six talent peaks project in Jiangsu Province (WSN-039) and the talents program of Jiangsu Cancer Hospital (YC201807).Research Project of Jiangsu Cancer Hospital (No. ZM202007).

Conflicts of interest: All authors have completed the ICMJE uniform disclosure form. The authors have no conflicts of interest to declare.

Figure legend

Figure 1. Clinical outcomes. A, ORR (objective response rate) and DCR (disease control rate) of all patients. B, PFS (progression-free survival) of all patients. C, DCR of patients with or without radiotherapy and DCR of patients with different ECOG performance status. D, ORR of patients treated with ICIs as first-line or later treatment. *: $p<0.05$

Figure 2. Kaplan-Meier curves. A, PFS of patients treated with ICIs as first-line or later treatment. B, PFS of patients treated with ICIs alone or in combination with other drugs. C, PFS of different combination groups. D, PFS of patients with or without radiotherapy.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. *CA Cancer J Clin.* 2019;69(1):7-34.

2. Liang X, Bi S, Yang W, et al. Reprint of: Epidemiological serosurvey of Hepatitis B in China–declining HBV prevalence due to Hepatitis B vaccination. *Vaccine.* 2013;31 Suppl 9:J21-28.

3. Liu J, Liang W, Jing W, Liu M. Countdown to 2030: eliminating hepatitis B disease, China. *Bull World Health Organ.*2019;97(3):230-238.

4. Nakamoto N, Cho H, Shaked A, et al. Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. *PLoS Pathog.* 2009;5(2):e1000313.

5. Herbst RS, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. *The Lancet.*2016;387(10027):1540-1550.

6. Pu D, Yin L, Zhou Y, et al. Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer: A systematic review. *Medicine (Baltimore).* 2020;99(5):e19013.

7. Byeon S, Cho JH, Jung HA, et al. PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence.*Cancer Med.* 2020;9(7):2352-2362.

8. Mok TSK, Wu Y-L, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. *The Lancet.*2019;393(10183):1819-1830.

9. Garassino MC, Gadgeel S, Esteban E, et al. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. *The Lancet Oncology.* 2020;21(3):387-397.

10. Paz-Ares L, Vicente D, Tafreshi A, et al. A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407. *J Thorac Oncol.* 2020;15(10):1657-1669.

11. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. *N Engl J Med.*2015;373(2):123-135.

12. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. *N Engl J Med.*2015;373(17):1627-1639.

13. Chajon E, Castelli J, Marsiglia H, De Crevoisier R. The synergistic effect of radiotherapy and immunotherapy: A promising but not simple partnership. *Crit Rev Oncol Hematol.* 2017;111:124-132.

14. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. *N Engl J Med.* 2015;372(21):2018-2028.

Figure 1



Figure 2



Hosted file

Table 1 .docx available at https://authorea.com/users/360005/articles/530986-efficacy-and-safety-of-pd-1-immune-checkpoint-inhibitors-in-locally-advanced-and-advanced-non-small-cell-lung-cancer-patients-with-chronic-viral-infection

Hosted file

Table 2 .docx available at https://authorea.com/users/360005/articles/530986-efficacy-and-

safety-of-pd-1-immune-checkpoint-inhibitors-in-locally-advanced-and-advanced-non-small-cell-lung-cancer-patients-with-chronic-viral-infection

Hosted file

Table 3 .docx available at https://authorea.com/users/360005/articles/530986-efficacy-and-safety-of-pd-1-immune-checkpoint-inhibitors-in-locally-advanced-and-advanced-non-small-cell-lung-cancer-patients-with-chronic-viral-infection

Hosted file

Table 4 .docx available at https://authorea.com/users/360005/articles/530986-efficacy-and-safety-of-pd-1-immune-checkpoint-inhibitors-in-locally-advanced-and-advanced-non-small-cell-lung-cancer-patients-with-chronic-viral-infection